Phase 1Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

Sponsor
Tobira Therapeutics, Inc. (Industry)
Enrollment
48 enrolled
Conditions
Healthy
Interventions
Cenicriviroc; Omeprazole; Famotidine
Ages
adults
Registry
NCT02684799

Full record on ClinicalTrials.gov

From the registry

This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC

Primary outcomes

  • Pharmacokinetic Assessment of CVC, as measured by maximum plasma concentration (Cmax)
  • Pharmacokinetic Assessment of CVC, as measured by minimum plasma concentration (Cmin)
  • Pharmacokinetic Assessment of CVC, as measured by area under the plasma concentration-time curve (AUC)

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started